Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 226 entries
Sorted by: Best Match Show Resources per page
Hereditary angioedema: Linking complement regulation to the coagulation system.

Research and practice in thrombosis and haemostasis

Levi M, Cohn DM, Zeerleder S.
PMID: 30656274
Res Pract Thromb Haemost. 2018 Dec 16;3(1):38-43. doi: 10.1002/rth2.12175. eCollection 2019 Jan.

Congenital deficiency of C1 inhibitor, the main inhibitor of the classic complement system pathway, leads to paroxysmal angioedema (hereditary angioedema) that can be debilitating or life-threatening for affected patients. In the past few years many new insights on the...

Cite
Levi M, Cohn DM, Zeerleder S. Hereditary angioedema: Linking complement regulation to the coagulation system. Res Pract Thromb Haemost. 2018;3(1):38-43doi: 10.1002/rth2.12175.
Levi, M., Cohn, D. M., & Zeerleder, S. (2019). Hereditary angioedema: Linking complement regulation to the coagulation system. Research and practice in thrombosis and haemostasis, 3(1), 38-43. https://doi.org/10.1002/rth2.12175
Levi, Marcel, et al. "Hereditary angioedema: Linking complement regulation to the coagulation system." Research and practice in thrombosis and haemostasis vol. 3,1 (2019): 38-43. doi: https://doi.org/10.1002/rth2.12175
Levi M, Cohn DM, Zeerleder S. Hereditary angioedema: Linking complement regulation to the coagulation system. Res Pract Thromb Haemost. 2018 Dec 16;3(1):38-43. doi: 10.1002/rth2.12175. eCollection 2019 Jan. PMID: 30656274; PMCID: PMC6332742.
Copy Download .nbib Format: NLM
Correction: Optimizing Text Messages to Promote Engagement With Internet Smoking Cessation Treatment: Results From a Factorial Screening Experiment.

Journal of medical Internet research

Graham AL, Papandonatos GD, Jacobs MA, Amato MS, Cha S, Cohn AM, Abroms LC, Whittaker R.
PMID: 32721924
J Med Internet Res. 2020 Jul 28;22(7):e21027. doi: 10.2196/21027.

[This corrects the article DOI: 10.2196/17734.].

Cite
Graham AL, Papandonatos GD, Jacobs MA, et al. Correction: Optimizing Text Messages to Promote Engagement With Internet Smoking Cessation Treatment: Results From a Factorial Screening Experiment. J Med Internet Res. 2020;22(7):e21027doi: 10.2196/21027.
Graham, A. L., Papandonatos, G. D., Jacobs, M. A., Amato, M. S., Cha, S., Cohn, A. M., Abroms, L. C., & Whittaker, R. (2020). Correction: Optimizing Text Messages to Promote Engagement With Internet Smoking Cessation Treatment: Results From a Factorial Screening Experiment. Journal of medical Internet research, 22(7), e21027. https://doi.org/10.2196/21027
Graham, Amanda L, et al. "Correction: Optimizing Text Messages to Promote Engagement With Internet Smoking Cessation Treatment: Results From a Factorial Screening Experiment." Journal of medical Internet research vol. 22,7 (2020): e21027. doi: https://doi.org/10.2196/21027
Graham AL, Papandonatos GD, Jacobs MA, Amato MS, Cha S, Cohn AM, Abroms LC, Whittaker R. Correction: Optimizing Text Messages to Promote Engagement With Internet Smoking Cessation Treatment: Results From a Factorial Screening Experiment. J Med Internet Res. 2020 Jul 28;22(7):e21027. doi: 10.2196/21027. PMID: 32721924; PMCID: PMC7420627.
Copy Download .nbib Format: NLM
Mitochondria as a Target for Mitigating Sarcopenia.

Frontiers in physiology

Coen PM, Musci RV, Hinkley JM, Miller BF.
PMID: 30687111
Front Physiol. 2019 Jan 10;9:1883. doi: 10.3389/fphys.2018.01883. eCollection 2018.

Sarcopenia is the loss of muscle mass, strength, and physical function that is characteristic of aging. The progression of sarcopenia is gradual but may be accelerated by periods of muscle loss during physical inactivity secondary to illness or injury....

Cite
Coen PM, Musci RV, Hinkley JM, et al. Mitochondria as a Target for Mitigating Sarcopenia. Front Physiol. 2019;9:1883doi: 10.3389/fphys.2018.01883.
Coen, P. M., Musci, R. V., Hinkley, J. M., & Miller, B. F. (2018). Mitochondria as a Target for Mitigating Sarcopenia. Frontiers in physiology, 91883. https://doi.org/10.3389/fphys.2018.01883
Coen, Paul M, et al. "Mitochondria as a Target for Mitigating Sarcopenia." Frontiers in physiology vol. 9 (2018): 1883. doi: https://doi.org/10.3389/fphys.2018.01883
Coen PM, Musci RV, Hinkley JM, Miller BF. Mitochondria as a Target for Mitigating Sarcopenia. Front Physiol. 2019 Jan 10;9:1883. doi: 10.3389/fphys.2018.01883. eCollection 2018. PMID: 30687111; PMCID: PMC6335344.
Copy Download .nbib Format: NLM
Utilization, receptivity and reactivity to Interactive Voice Response daily monitoring in risky drinking smokers who are motivated to quit.

Tobacco induced diseases

Cohn AM, Elmasry H, Ehlke SJ.
PMID: 31516425
Tob Induc Dis. 2018 May 30;16:25. doi: 10.18332/tid/84972. eCollection 2018.

INTRODUCTION: Interactive Voice Response (IVR) technology has become an increasingly popular and valid method for collecting Ecological Momentary Assessment (EMA) data on a variety of health-risk behaviors, including daily alcohol use and cigarette smoking, and for stimulating behavior change....

Cite
Cohn AM, Elmasry H, Ehlke SJ. Utilization, receptivity and reactivity to Interactive Voice Response daily monitoring in risky drinking smokers who are motivated to quit. Tob Induc Dis. 2018;16:25doi: 10.18332/tid/84972.
Cohn, A. M., Elmasry, H., & Ehlke, S. J. (2018). Utilization, receptivity and reactivity to Interactive Voice Response daily monitoring in risky drinking smokers who are motivated to quit. Tobacco induced diseases, 1625. https://doi.org/10.18332/tid/84972
Cohn, Amy M, et al. "Utilization, receptivity and reactivity to Interactive Voice Response daily monitoring in risky drinking smokers who are motivated to quit." Tobacco induced diseases vol. 16 (2018): 25. doi: https://doi.org/10.18332/tid/84972
Cohn AM, Elmasry H, Ehlke SJ. Utilization, receptivity and reactivity to Interactive Voice Response daily monitoring in risky drinking smokers who are motivated to quit. Tob Induc Dis. 2018 May 30;16:25. doi: 10.18332/tid/84972. eCollection 2018. PMID: 31516425; PMCID: PMC6659485.
Copy Download .nbib Format: NLM
Profiling beneficial and potential adverse effects of MeCP2 overexpression in a hypomorphic Rett syndrome mouse model.

Genes, brain, and behavior

Vermudez SAD, Gogliotti RG, Arthur B, Buch A, Morales C, Moxley Y, Rajpal H, Conn PJ, Niswender CM.
PMID: 34002468
Genes Brain Behav. 2022 Jan;21(1):e12752. doi: 10.1111/gbb.12752. Epub 2021 May 28.

De novo loss-of-function mutations in methyl-CpG-binding protein 2 (MeCP2) lead to the neurodevelopmental disorder Rett syndrome (RTT). Despite promising results from strategies aimed at increasing MeCP2 levels, additional studies exploring how hypomorphic MeCP2 mutations impact the therapeutic window are...

Cite
Vermudez SAD, Gogliotti RG, Arthur B, et al. Profiling beneficial and potential adverse effects of MeCP2 overexpression in a hypomorphic Rett syndrome mouse model. Genes Brain Behav. 2021;21(1):e12752doi: 10.1111/gbb.12752.
Vermudez, S. A. D., Gogliotti, R. G., Arthur, B., Buch, A., Morales, C., Moxley, Y., Rajpal, H., Conn, P. J., & Niswender, C. M. (2022). Profiling beneficial and potential adverse effects of MeCP2 overexpression in a hypomorphic Rett syndrome mouse model. Genes, brain, and behavior, 21(1), e12752. https://doi.org/10.1111/gbb.12752
Vermudez, Sheryl Anne D, et al. "Profiling beneficial and potential adverse effects of MeCP2 overexpression in a hypomorphic Rett syndrome mouse model." Genes, brain, and behavior vol. 21,1 (2022): e12752. doi: https://doi.org/10.1111/gbb.12752
Vermudez SAD, Gogliotti RG, Arthur B, Buch A, Morales C, Moxley Y, Rajpal H, Conn PJ, Niswender CM. Profiling beneficial and potential adverse effects of MeCP2 overexpression in a hypomorphic Rett syndrome mouse model. Genes Brain Behav. 2022 Jan;21(1):e12752. doi: 10.1111/gbb.12752. Epub 2021 May 28. PMID: 34002468; PMCID: PMC8599502.
Copy Download .nbib Format: NLM
Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment.

AIDS (London, England)

Swindells S, Lutz T, Van Zyl L, Porteiro N, Stoll M, Mitha E, Shon A, Benn P, Huang JO, Harrington CM, Hove K, Ford SL, Talarico CL, Chounta V, Crauwels H, Van Solingen-Ristea R, Vanveggel S, Margolis DA, Smith KY, Vandermeulen K, Spreen WR.
PMID: 34261093
AIDS. 2022 Feb 01;36(2):185-194. doi: 10.1097/QAD.0000000000003025.

BACKGROUND: ATLAS (NCT02951052), a phase 3, multicenter, open-label study, demonstrated that switching to injectable cabotegravir (CAB) with rilpivirine (RPV) long-acting dosed every 4 weeks was noninferior at week (W) 48 to continuing three-drug daily oral current antiretroviral therapy (CAR)....

Cite
Swindells S, Lutz T, Van Zyl L, et al. Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment. AIDS. 2022;36(2):185-194doi: 10.1097/QAD.0000000000003025.
Swindells, S., Lutz, T., Van Zyl, L., Porteiro, N., Stoll, M., Mitha, E., Shon, A., Benn, P., Huang, J. O., Harrington, C. M., Hove, K., Ford, S. L., Talarico, C. L., Chounta, V., Crauwels, H., Van Solingen-Ristea, R., Vanveggel, S., Margolis, D. A., Smith, K. Y., Vandermeulen, K., & Spreen, W. R. (2022). Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment. AIDS (London, England), 36(2), 185-194. https://doi.org/10.1097/QAD.0000000000003025
Swindells, Susan, et al. "Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment." AIDS (London, England) vol. 36,2 (2022): 185-194. doi: https://doi.org/10.1097/QAD.0000000000003025
Swindells S, Lutz T, Van Zyl L, Porteiro N, Stoll M, Mitha E, Shon A, Benn P, Huang JO, Harrington CM, Hove K, Ford SL, Talarico CL, Chounta V, Crauwels H, Van Solingen-Ristea R, Vanveggel S, Margolis DA, Smith KY, Vandermeulen K, Spreen WR. Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment. AIDS. 2022 Feb 01;36(2):185-194. doi: 10.1097/QAD.0000000000003025. PMID: 34261093; PMCID: PMC8711605.
Copy Download .nbib Format: NLM
Optimizing Text Messages to Promote Engagement With Internet Smoking Cessation Treatment: Results From a Factorial Screening Experiment.

Journal of medical Internet research

Graham AL, Papandonatos GD, Jacobs MA, Amato MS, Cha S, Cohn AM, Abroms LC, Whittaker R.
PMID: 32238338
J Med Internet Res. 2020 Apr 02;22(4):e17734. doi: 10.2196/17734.

BACKGROUND: Smoking remains a leading cause of preventable death and illness. Internet interventions for smoking cessation have the potential to significantly impact public health, given their broad reach and proven effectiveness. Given the dose-response association between engagement and behavior...

Cite
Graham AL, Papandonatos GD, Jacobs MA, et al. Optimizing Text Messages to Promote Engagement With Internet Smoking Cessation Treatment: Results From a Factorial Screening Experiment. J Med Internet Res. 2020;22(4):e17734doi: 10.2196/17734.
Graham, A. L., Papandonatos, G. D., Jacobs, M. A., Amato, M. S., Cha, S., Cohn, A. M., Abroms, L. C., & Whittaker, R. (2020). Optimizing Text Messages to Promote Engagement With Internet Smoking Cessation Treatment: Results From a Factorial Screening Experiment. Journal of medical Internet research, 22(4), e17734. https://doi.org/10.2196/17734
Graham, Amanda L, et al. "Optimizing Text Messages to Promote Engagement With Internet Smoking Cessation Treatment: Results From a Factorial Screening Experiment." Journal of medical Internet research vol. 22,4 (2020): e17734. doi: https://doi.org/10.2196/17734
Graham AL, Papandonatos GD, Jacobs MA, Amato MS, Cha S, Cohn AM, Abroms LC, Whittaker R. Optimizing Text Messages to Promote Engagement With Internet Smoking Cessation Treatment: Results From a Factorial Screening Experiment. J Med Internet Res. 2020 Apr 02;22(4):e17734. doi: 10.2196/17734. PMID: 32238338; PMCID: PMC7386536.
Copy Download .nbib Format: NLM
Completing an interdisciplinary outpatient intervention improves patient rehabilitation goals following a mild traumatic brain injury.

Physiotherapy theory and practice

Bonn MM, Dickey JP, Moran B, McGuire S, Graham L.
PMID: 35001810
Physiother Theory Pract. 2022 Jan 08;1-7. doi: 10.1080/09593985.2021.2022046. Epub 2022 Jan 08.

BACKGROUND: Individualized and interdisciplinary rehabilitation programs are recommended following a mild traumatic brain injury (mTBI), but often have long waitlists. Accordingly, innovative evidence-based programs are needed.OBJECTIVES: The first objective of this study was to determine the number and types...

Cite
Bonn MM, Dickey JP, Moran B, et al. Completing an interdisciplinary outpatient intervention improves patient rehabilitation goals following a mild traumatic brain injury. Physiother Theory Pract. 2022;1-7doi: 10.1080/09593985.2021.2022046.
Bonn, M. M., Dickey, J. P., Moran, B., McGuire, S., & Graham, L. (2022). Completing an interdisciplinary outpatient intervention improves patient rehabilitation goals following a mild traumatic brain injury. Physiotherapy theory and practice, 1-7. https://doi.org/10.1080/09593985.2021.2022046
Bonn, Marquise M, et al. "Completing an interdisciplinary outpatient intervention improves patient rehabilitation goals following a mild traumatic brain injury." Physiotherapy theory and practice vol. (2022): 1-7. doi: https://doi.org/10.1080/09593985.2021.2022046
Bonn MM, Dickey JP, Moran B, McGuire S, Graham L. Completing an interdisciplinary outpatient intervention improves patient rehabilitation goals following a mild traumatic brain injury. Physiother Theory Pract. 2022 Jan 08;1-7. doi: 10.1080/09593985.2021.2022046. Epub 2022 Jan 08. PMID: 35001810.
Copy Download .nbib Format: NLM
Profiling beneficial and potential adverse effects of MeCP2 overexpression in a hypomorphic Rett syndrome mouse model.

Genes, brain, and behavior

Vermudez SAD, Gogliotti RG, Arthur B, Buch A, Morales C, Moxley Y, Rajpal H, Conn PJ, Niswender CM.
PMID: 34002468
Genes Brain Behav. 2022 Jan;21(1):e12752. doi: 10.1111/gbb.12752. Epub 2021 May 28.

De novo loss-of-function mutations in methyl-CpG-binding protein 2 (MeCP2) lead to the neurodevelopmental disorder Rett syndrome (RTT). Despite promising results from strategies aimed at increasing MeCP2 levels, additional studies exploring how hypomorphic MeCP2 mutations impact the therapeutic window are...

Cite
Vermudez SAD, Gogliotti RG, Arthur B, et al. Profiling beneficial and potential adverse effects of MeCP2 overexpression in a hypomorphic Rett syndrome mouse model. Genes Brain Behav. 2021;21(1):e12752doi: 10.1111/gbb.12752.
Vermudez, S. A. D., Gogliotti, R. G., Arthur, B., Buch, A., Morales, C., Moxley, Y., Rajpal, H., Conn, P. J., & Niswender, C. M. (2022). Profiling beneficial and potential adverse effects of MeCP2 overexpression in a hypomorphic Rett syndrome mouse model. Genes, brain, and behavior, 21(1), e12752. https://doi.org/10.1111/gbb.12752
Vermudez, Sheryl Anne D, et al. "Profiling beneficial and potential adverse effects of MeCP2 overexpression in a hypomorphic Rett syndrome mouse model." Genes, brain, and behavior vol. 21,1 (2022): e12752. doi: https://doi.org/10.1111/gbb.12752
Vermudez SAD, Gogliotti RG, Arthur B, Buch A, Morales C, Moxley Y, Rajpal H, Conn PJ, Niswender CM. Profiling beneficial and potential adverse effects of MeCP2 overexpression in a hypomorphic Rett syndrome mouse model. Genes Brain Behav. 2022 Jan;21(1):e12752. doi: 10.1111/gbb.12752. Epub 2021 May 28. PMID: 34002468; PMCID: PMC8599502.
Copy Download .nbib Format: NLM
Discovery of the First Selective M.

ACS pharmacology & translational science

Moehle MS, Bender AM, Dickerson JW, Foster DJ, Qi A, Cho HP, Donsante Y, Peng W, Bryant Z, Stillwell KJ, Bridges TM, Chang S, Watson KJ, O'Neill JC, Engers JL, Peng L, Rodriguez AL, Niswender CM, Lindsley CW, Hess EJ, Conn PJ, Rook JM.
PMID: 34423268
ACS Pharmacol Transl Sci. 2021 Aug 02;4(4):1306-1321. doi: 10.1021/acsptsci.0c00162. eCollection 2021 Aug 13.

Nonselective antagonists of muscarinic acetylcholine receptors (mAChRs) that broadly inhibit all five mAChR subtypes provide an efficacious treatment for some movement disorders, including Parkinson's disease and dystonia. Despite their efficacy in these and other central nervous system disorders, antimuscarinic...

Cite
Moehle MS, Bender AM, Dickerson JW, et al. Discovery of the First Selective M. ACS Pharmacol Transl Sci. 2021;4(4):1306-1321doi: 10.1021/acsptsci.0c00162.
Moehle, M. S., Bender, A. M., Dickerson, J. W., Foster, D. J., Qi, A., Cho, H. P., Donsante, Y., Peng, W., Bryant, Z., Stillwell, K. J., Bridges, T. M., Chang, S., Watson, K. J., O'Neill, J. C., Engers, J. L., Peng, L., Rodriguez, A. L., Niswender, C. M., Lindsley, C. W., Hess, E. J., Conn, P. J., & Rook, J. M. (2021). Discovery of the First Selective M. ACS pharmacology & translational science, 4(4), 1306-1321. https://doi.org/10.1021/acsptsci.0c00162
Moehle, Mark S, et al. "Discovery of the First Selective M." ACS pharmacology & translational science vol. 4,4 (2021): 1306-1321. doi: https://doi.org/10.1021/acsptsci.0c00162
Moehle MS, Bender AM, Dickerson JW, Foster DJ, Qi A, Cho HP, Donsante Y, Peng W, Bryant Z, Stillwell KJ, Bridges TM, Chang S, Watson KJ, O'Neill JC, Engers JL, Peng L, Rodriguez AL, Niswender CM, Lindsley CW, Hess EJ, Conn PJ, Rook JM. Discovery of the First Selective M. ACS Pharmacol Transl Sci. 2021 Aug 02;4(4):1306-1321. doi: 10.1021/acsptsci.0c00162. eCollection 2021 Aug 13. PMID: 34423268; PMCID: PMC8369681.
Copy Download .nbib Format: NLM
Linking indirect effects of cytomegalovirus in transplantation to modulation of monocyte innate immune function.

Science advances

Sen P, Wilkie AR, Ji F, Yang Y, Taylor IJ, Velazquez-Palafox M, Vanni EAH, Pesola JM, Fernandez R, Chen H, Morsett LM, Abels ER, Piper M, Lane RJ, Hickman SE, Means TK, Rosenberg ES, Sadreyev RI, Li B, Coen DM, Fishman JA, El Khoury J.
PMID: 32494628
Sci Adv. 2020 Apr 22;6(17):eaax9856. doi: 10.1126/sciadv.aax9856. eCollection 2020 Apr.

Cytomegalovirus (CMV) is an important cause of morbidity and mortality in the immunocompromised host. In transplant recipients, a variety of clinically important "indirect effects" are attributed to immune modulation by CMV, including increased mortality from fungal disease, allograft dysfunction...

Cite
Sen P, Wilkie AR, Ji F, et al. Linking indirect effects of cytomegalovirus in transplantation to modulation of monocyte innate immune function. Sci Adv. 2020;6(17):eaax9856doi: 10.1126/sciadv.aax9856.
Sen, P., Wilkie, A. R., Ji, F., Yang, Y., Taylor, I. J., Velazquez-Palafox, M., Vanni, E. A. H., Pesola, J. M., Fernandez, R., Chen, H., Morsett, L. M., Abels, E. R., Piper, M., Lane, R. J., Hickman, S. E., Means, T. K., Rosenberg, E. S., Sadreyev, R. I., Li, B., Coen, D. M., Fishman, J. A., & El Khoury, J. (2020). Linking indirect effects of cytomegalovirus in transplantation to modulation of monocyte innate immune function. Science advances, 6(17), eaax9856. https://doi.org/10.1126/sciadv.aax9856
Sen, Pritha, et al. "Linking indirect effects of cytomegalovirus in transplantation to modulation of monocyte innate immune function." Science advances vol. 6,17 (2020): eaax9856. doi: https://doi.org/10.1126/sciadv.aax9856
Sen P, Wilkie AR, Ji F, Yang Y, Taylor IJ, Velazquez-Palafox M, Vanni EAH, Pesola JM, Fernandez R, Chen H, Morsett LM, Abels ER, Piper M, Lane RJ, Hickman SE, Means TK, Rosenberg ES, Sadreyev RI, Li B, Coen DM, Fishman JA, El Khoury J. Linking indirect effects of cytomegalovirus in transplantation to modulation of monocyte innate immune function. Sci Adv. 2020 Apr 22;6(17):eaax9856. doi: 10.1126/sciadv.aax9856. eCollection 2020 Apr. PMID: 32494628; PMCID: PMC7176434.
Copy Download .nbib Format: NLM
Association between interleukin-17F rs763780 polymorphism and psoriasis risk: A meta-analysis.

Indian journal of dermatology, venereology and leprology

Xiang Z, Hao Z, Cui P, Lin L, Chen M, Chen PM.
PMID: 34877855
Indian J Dermatol Venereol Leprol. 2021 Oct 30;1-6. doi: 10.25259/IJDVL_1401_20. Epub 2021 Oct 30.

BACKGROUND: The polymorphism of interleukin-17F rs763780 has been found to have a probable association with increased risk of developing psoriasis.AIMS: This study aims to get a more convincing estimation of the association between the interleukin-17F rs763780 T /C polymorphism...

Cite
Xiang Z, Hao Z, Cui P, et al. Association between interleukin-17F rs763780 polymorphism and psoriasis risk: A meta-analysis. Indian J Dermatol Venereol Leprol. 2021;1-6doi: 10.25259/IJDVL_1401_20.
Xiang, Z., Hao, Z., Cui, P., Lin, L., Chen, M., & Chen, P. M. (2021). Association between interleukin-17F rs763780 polymorphism and psoriasis risk: A meta-analysis. Indian journal of dermatology, venereology and leprology, 1-6. https://doi.org/10.25259/IJDVL_1401_20
Xiang, Zhi, et al. "Association between interleukin-17F rs763780 polymorphism and psoriasis risk: A meta-analysis." Indian journal of dermatology, venereology and leprology vol. (2021): 1-6. doi: https://doi.org/10.25259/IJDVL_1401_20
Xiang Z, Hao Z, Cui P, Lin L, Chen M, Chen PM. Association between interleukin-17F rs763780 polymorphism and psoriasis risk: A meta-analysis. Indian J Dermatol Venereol Leprol. 2021 Oct 30;1-6. doi: 10.25259/IJDVL_1401_20. Epub 2021 Oct 30. PMID: 34877855.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 226 entries